Working… Menu
Trial record 2 of 3 for:    "Pituitary Adenoma 4, Acth-Secreting" | "Neurotransmitter Agents"

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00889525
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : April 29, 2009
Information provided by:
Seth Gordhandas Sunderdas Medical College

Brief Summary:

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Condition or disease Intervention/treatment Phase
Cushing's Disease Corticotroph Adenoma Drug: Cabergoline Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Study Start Date : November 2007

Arm Intervention/treatment
Experimental: Cabergoline Drug: Cabergoline
Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.

Primary Outcome Measures :
  1. Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology

Exclusion Criteria:

  • Patient's intolerance to drug or known sensitivity to ergot derivatives
  • Pregnancy, lactation or female wishing to be pregnant
  • Any serious medical illness
  • Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00889525

Layout table for location information
Seth GSMC & KEM hospital
Mumbai, Maharashtra, India, 4000012
Sponsors and Collaborators
Seth Gordhandas Sunderdas Medical College
Layout table for investigator information
Principal Investigator: Nalini S Shah, DM Seth GSMC and KEM hospital, Mumbai

Layout table for additonal information
Responsible Party: Dr Nalini S Shah, Seth Gordhandas Sunderdas Medical College& KEM Hospital Identifier: NCT00889525     History of Changes
Other Study ID Numbers: EC/104/2005
First Posted: April 29, 2009    Key Record Dates
Last Update Posted: April 29, 2009
Last Verified: April 2009
Keywords provided by Seth Gordhandas Sunderdas Medical College:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pituitary ACTH Hypersecretion
Neurotransmitter Agents
Pituitary Neoplasms
ACTH-Secreting Pituitary Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs